The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
EngstromP.F., BensonA.B.III, CohenA.NCCN colorectal cancer practice guidelines. Oncology.1996; 10(suppl 1): 140–75.
HeidelbergerC., ChaudhuriN.K., DannebergP.Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature.1957; 179: 663–6.
4.
BertinoJ.R.Chemotherapy of colorectal cancer: history and new themes. Semin Oncol.1997; 24(suppl 1)S18-3–S18-7.
5.
PoonM.A., O'ConnellM.J., MoertelC.G.Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol.1989; 7: 1407–17.
6.
SaltzL.B., CoxJ.V., BlankeC.Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med.2000; 343: 905–14.
7.
de GramontA., FigerA., SeymourM.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol.2000; 18: 2938–47.
8.
LeichmanC.G., FlemingT.R., MuggiaF.M.Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol.1995; 13: 1303–11.
9.
ArandaE., Diaz-RubioE., CervantesA.Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol.1998; 9: 727–31.
10.
de GramontA., BossetJ.F., MilanC.Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Inter-group study. J Clin Oncol.1997; 15: 808–15.
11.
MachoverD.A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer.1997; 80: 1179–87.
12.
JagerE., HeikeM., BernhardH.Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial. J Clin Oncol.1996; 14: 2274–9.
13.
KohneC.H., SchoffskiP., WilkeH.Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol.1998; 16: 418–26.
14.
BornerM.M., CastiglioneM., BacchiM.The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Ann Oncol.1998; 9: 535–41.
15.
SobreroA.F., AscheleC., BertinoJ.R.Fluorouracil in colorectal cancer – a tale of two drugs: Implications for biochemical modulation. J Clin Oncol.1997; 15: 368–81.
16.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
17.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56:729–64.
18.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11: 57–89.
19.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
